Lexaria Bioscience - Warrants (11/01/2026) Receivables

As of the most recent data (May 2026), LEXXW shows a receivables of $49K. That compares with $360K in the prior-year period — down 86.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LEXXW's receivables is now $49K (was $360K) — a 86.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Lexaria Bioscience - Warrants (11/01/2026) is outperforming or lagging.

Tracking LEXXW's receivables over time shows whether Lexaria Bioscience - Warrants (11/01/2026) is scaling, shrinking, or reshaping that part of the business. The current reading is $49K That compares with $360K in the prior-year period — down 86.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Lexaria Bioscience - Warrants (11/01/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $49K) with ownership activity and broader fundamentals.

Lexaria Bioscience - Warrants (11/01/2026)'s receivables is $49K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.